Intech Biopharm (ROCO:6461) Piotroski F-Score: 5 (As of Jul. 18, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
55 GF Score
Price NT$15.45
GF Value NT$87.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm Piotroski F-Score?

Intech Biopharm ROCO:6461 -0.64% 55 Piotroski F-Score is 5 as of Jul. 18, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates ROCO:6461 with a GF Score™ of 55/100 and a GF Value™ of NT$87.90 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,333 Biotechnology companies, Intech Biopharm ranks better than 84.7% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Intech Biopharm has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Intech Biopharm's Piotroski F-Score or its related term are showing as below:

ROCO:6461' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 5

During the past 13 years, the highest Piotroski F-Score of Intech Biopharm was 5. The lowest was 1. And the median was 3.

Intech Biopharm  (ROCO:6461) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Intech Biopharm Piotroski F-Score Related Terms


Intech Biopharm Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Intech Biopharm's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intech Biopharm Piotroski F-Score Chart

Intech Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 1.00 3.00 3.00 5.00

Intech Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 5.00 4.00 5.00

ROCO:6461 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Intech Biopharm's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intech Biopharm Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's Piotroski F-Score falls into.


ROCO:6461
55GF Score
Intech Biopharm Ltd ROCO:6461
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -88.352 + -33.22 + -144.082 + -123.378 = NT$-389.0 Mil.
Cash Flow from Operations was -98.353 + -75.175 + -123.209 + -64.395 = NT$-361.1 Mil.
Revenue was 7.656 + 87.767 + 7.28 + 4.824 = NT$107.5 Mil.
Gross Profit was -40.509 + 25.506 + -48.242 + -47.697 = NT$-110.9 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(2395.802 + 2372.473 + 2731.172 + 2496.569 + 2350.952) / 5 = NT$2469.3936 Mil.
Total Assets at the begining of this year (Dec24) was NT$2,395.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$995.5 Mil.
Total Current Assets was NT$403.1 Mil.
Total Current Liabilities was NT$243.3 Mil.
Net Income was -74.901 + -92.621 + -95.99 + -104.695 = NT$-368.2 Mil.

Revenue was 14.767 + 5.207 + 8.655 + 11.15 = NT$39.8 Mil.
Gross Profit was -33.104 + -41.333 + -42.862 + -40.326 = NT$-157.6 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(2711.068 + 2721.28 + 2557.107 + 2468.454 + 2395.802) / 5 = NT$2570.7422 Mil.
Total Assets at the begining of last year (Dec23) was NT$2,711.1 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,187.6 Mil.
Total Current Assets was NT$410.3 Mil.
Total Current Liabilities was NT$386.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Intech Biopharm's current Net Income (TTM) was -389.0. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Intech Biopharm's current Cash Flow from Operations (TTM) was -361.1. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-389.032/2395.802
=-0.1623807

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-368.207/2711.068
=-0.13581622

Intech Biopharm's return on assets of this year was -0.1623807. Intech Biopharm's return on assets of last year was -0.13581622. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Intech Biopharm's current Net Income (TTM) was -389.0. Intech Biopharm's current Cash Flow from Operations (TTM) was -361.1. ==> -361.1 > -389.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=995.499/2469.3936
=0.403135

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1187.624/2570.7422
=0.46197709

Intech Biopharm's gearing of this year was 0.403135. Intech Biopharm's gearing of last year was 0.46197709. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=403.129/243.324
=1.65675807

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=410.324/386.644
=1.06124497

Intech Biopharm's current ratio of this year was 1.65675807. Intech Biopharm's current ratio of last year was 1.06124497. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Intech Biopharm's number of shares in issue this year was 164.008. Intech Biopharm's number of shares in issue last year was 146.619. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-110.942/107.527
=-1.03175947

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-157.625/39.779
=-3.96251791

Intech Biopharm's gross margin of this year was -1.03175947. Intech Biopharm's gross margin of last year was -3.96251791. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=107.527/2395.802
=0.04488142

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=39.779/2711.068
=0.01467282

Intech Biopharm's asset turnover of this year was 0.04488142. Intech Biopharm's asset turnover of last year was 0.01467282. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Intech Biopharm has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Intech Biopharm (ROCO:6461) has a Piotroski F-Score of 5 as of Jul. 18, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Intech Biopharm and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, Intech Biopharm's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, Intech Biopharm ranks #204 out of 1333 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Intech Biopharm's Piotroski F-Score too high?
Intech Biopharm's current Piotroski F-Score of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Intech Biopharm's value of 5 is 66.7% above this industry median. Based on the distribution chart, Intech Biopharm ranks #204 out of 1333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intech Biopharm ranks #204 out of 1333 companies for Piotroski F-Score. This places Intech Biopharm in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Intech Biopharm's value of 5 is 66.7% above this benchmark. Historically, Intech Biopharm's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Intech Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intech Biopharm's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Intech Biopharm and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intech Biopharm's current Piotroski F-Score is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.90, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current Piotroski F-Score is 5, which is 67% above median its 10-year median of 3.00 and 66.7% above the Biotechnology industry median of 3.00. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current Piotroski F-Score is 5 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.90. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • Piotroski F-Score: 5 (67% above median its 10-year median of 3.00)
  • GF Value™: NT$87.90 vs. price of NT$15.45 (82.4% below fair value)
  • GF Score™: 55/100 with 6 warning signs
  • Industry Position: 66.7% above the Biotechnology median (#204 of 1333)

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score

Get the complete analysis for ROCO:6461

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.45
Price
NT$87.90
GF Value